Citadel Advisors’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.2M | Sell |
57,600
-3,100
| -5% | -$695K | ﹤0.01% | 2861 |
|
|
2025
Q4 | $12.9M | Sell |
60,700
-33,100
| -35% | -$6.84M | ﹤0.01% | 2905 |
|
|
2025
Q3 | $18.6M | Buy |
93,800
+74,100
| +376% | +$13.8M | ﹤0.01% | 2424 |
|
|
2025
Q2 | $3.4M | Sell |
19,700
-9,400
| -32% | -$1.53M | ﹤0.01% | 4759 |
|
|
2025
Q1 | $4.54M | Buy |
29,100
+17,000
| +140% | +$2.43M | ﹤0.01% | 4036 |
|
|
2024
Q4 | $1.67M | Sell |
12,100
-7,700
| -39% | -$1.01M | ﹤0.01% | 6000 |
|
|
2024
Q3 | $2.96M | Sell |
19,800
-12,800
| -39% | -$1.73M | ﹤0.01% | 4809 |
|
|
2024
Q2 | $4.45M | Buy |
32,600
+17,200
| +112% | +$2.34M | ﹤0.01% | 3936 |
|
|
2024
Q1 | $2.33M | Sell |
15,400
-8,000
| -34% | -$1.14M | ﹤0.01% | 5227 |
|
|
2023
Q4 | $2.95M | Buy |
23,400
+4,700
| +25% | +$469K | ﹤0.01% | 4676 |
|
|
2023
Q3 | $1.75M | Sell |
18,700
-45,400
| -71% | -$4.25M | ﹤0.01% | 5471 |
|
|
2023
Q2 | $5.72M | Buy |
64,100
+11,300
| +21% | +$983K | ﹤0.01% | 3436 |
|
|
2023
Q1 | $5.66M | Sell |
52,800
-35,800
| -40% | -$4.1M | ﹤0.01% | 3596 |
|
|
2022
Q4 | $10.8M | Sell |
88,600
-75,700
| -46% | -$8.79M | ﹤0.01% | 2719 |
|
|
2022
Q3 | $17M | Buy |
164,300
+87,700
| +114% | +$8.31M | ﹤0.01% | 2067 |
|
|
2022
Q2 | $7.12M | Sell |
76,600
-55,700
| -42% | -$5.25M | ﹤0.01% | 3177 |
|
|
2022
Q1 | $15.5M | Buy |
132,300
+119,100
| +902% | +$13.8M | ﹤0.01% | 2311 |
|
|
2021
Q4 | $1.78M | Sell |
13,200
-30,600
| -70% | -$4.55M | ﹤0.01% | 6517 |
|
|
2021
Q3 | $6.98M | Buy |
43,800
+31,300
| +250% | +$4.28M | ﹤0.01% | 3682 |
|
|
2021
Q2 | $1.64M | Buy |
12,500
+900
| +8% | +$120K | ﹤0.01% | 7096 |
|
|
2021
Q1 | $1.5M | Buy |
11,600
+3,800
| +49% | +$578K | ﹤0.01% | 7108 |
|
|
2020
Q4 | $1.3M | Sell |
7,800
-4,400
| -36% | -$728K | ﹤0.01% | 6233 |
|
|
2020
Q3 | $1.88M | Sell |
12,200
-9,200
| -43% | -$1.32M | ﹤0.01% | 4824 |
|
|
2020
Q2 | $3.17M | Buy |
21,400
+4,700
| +28% | +$645K | ﹤0.01% | 3764 |
|
|
2020
Q1 | $1.88M | Sell |
16,700
-87,600
| -84% | -$11.4M | ﹤0.01% | 4243 |
|
|
2019
Q4 | $14.5M | Buy |
104,300
+51,100
| +96% | +$5.68M | 0.01% | 1810 |
|
|
2019
Q3 | $5.12M | Sell |
53,200
-134,000
| -72% | -$14.9M | ﹤0.01% | 3079 |
|
|
2019
Q2 | $21.6M | Sell |
187,200
-148,700
| -44% | -$17.8M | 0.01% | 1357 |
|
|
2019
Q1 | $39.5M | Buy |
335,900
+315,300
| +1,531% | +$27.6M | 0.02% | 837 |
|
|
2018
Q4 | $1.29M | Buy |
20,600
+6,700
| +48% | +$421K | ﹤0.01% | 4899 |
|
|
2018
Q3 | $985K | Buy |
13,900
+3,100
| +29% | +$213K | ﹤0.01% | 5569 |
|
|
2018
Q2 | $718K | Buy |
+10,800
| New | +$710K | ﹤0.01% | 5786 |
|
Other funds holding ASND
RCM
ACA
Citadel Advisors's ASND Position: Q1 2026 in Review
Citadel Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 519,516 shares — an estimated $116M sold.
Citadel Advisors first reported a position in ASND in Q1 2015 and held it in 34 quarters. The position peaked at $175M in Q1 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.
- Citadel Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 519,516 Ascendis Pharma A/S shares in Q1 2026, an estimated $116M.
- Citadel Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 34 quarters.
- Citadel Advisors's Ascendis Pharma A/S position peaked at $175M in Q1 2025.
- 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.